Objective:Methotrexate(MTX)can be safely administered to most patients but may cause severe toxicity in others.This study aimed to summarize the characteristics of high-dose methotrexate(HD-MTX)chemotherapy and to evaluate whether the modified dose-adjustment program was able to improve the maintenance of sufficient MTX exposure levels while minimizing toxicities.Methods:We evaluated 1172 cycles of high-dose MTX chemotherapy from 294 patients who were treated according to the CCCG-ALL-2015 protocol(clinical trial number:ChiCTR-IPR-14005706)and analyzed the data of actual MTX dosage,MTX concentration,toxicity,and prognosis.We compared data between the dose-adjustment Program 1(fixed 20％reduction in dose)and the dose-adjustment Program 2(dose-individualization based on reassessment of the creatine clearance rate and the MTX concentration-monitoring point at 16 h),which were applied if the MTX clearance was delayed in the previous cycle.Results:The patients who used Program 2 had higher actual MTX infusion doses and infusion rates and were able to better maintain the MTX concentration at 44 h at the established target value than those on Program 1(P＜0.001).No significant differences in toxicities were found between these two programs except that abnormal serum potassium levels and prolonged myelosuppression in intermediate-risk/high-risk patients were more frequently observed in patients using Program 2(P＜0.001).No significant correlations were observed between the MTX dose,dose-adjustment programs,or MTX concentrations and relapse-free survival.Conclusion:Adjusting the MTX dose using Program 2 is more efficient for maintaining sufficient MTX exposure without significantly increasing the toxicity.

Department of Pediatrics,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

[1]Ya-qing SHEN;Zhu-jun WANG;Xiao-yan WU;Kun LI;Zhong-jian WANG;Wen-fu XU;Fen ZHOU;Run-ming JIN-.Dose-individualization Efficiently Maintains Sufficient Exposure to Methotrexate without Additional Toxicity in High-dose Methotrexate Regimens for Pediatric Acute Lymphoblastic Leukemia)[J].当代医学科学(英文),2022(04):769-777

Maintains,Regimens,Lymphoblastic

Dose,individualization,Efficiently,Sufficient,Exposure,Methotrexate,without,Additional,Toxicity,High,Pediatric,Acute,Leukemia,Objective,MTX,safely,administered,most,patients,but,may,cause,severe,toxicity,others,This,study,aimed,summarize,characteristics,methotrexate,HD,chemotherapy,whether,modified,adjustment,was,able,improve,maintenance,sufficient,exposure,levels,while,minimizing,toxicities,Methods,We,evaluated,cycles,from,who,were,treated,according,CCCG,ALL,protocol,clinical,trial,number,ChiCTR,IPR,analyzed,data,actual,dosage,prognosis,compared,between,Program,fixed,reduction,reassessment,creatine,clearance,monitoring,point,which,applied,delayed,previous,Results,used,had,higher,infusion,doses,rates,better,established,target,value,than,those,No,differences,found,these,two,programs,except,that,abnormal,serum,potassium,prolonged,myelosuppression,intermediate,risk,more,frequently,observed,using,correlations,concentrations,relapse,free,survival,Conclusion,Adjusting,efficient,maintaining,significantly,increasing

0.527174